Johnson & Johnson JNJ

NYS: JNJ | ISIN: US4781601046   13/10/2026
248,61 USD (-5,73%)
(-5,73%)   13/10/2026
Grafiek Johnson & Johnson Grafiek Johnson & Johnson

Johnson & Johnson in het nieuws

12 oktober 2026 · New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups · Persbericht

12 oktober 2026 · TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease · Persbericht

9 oktober 2026 · New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis · Persbericht

2 oktober 2026 · Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy · Persbericht

29 september 2026 · Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG) · Persbericht

25 september 2026 · Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study · Persbericht

25 september 2026 · Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma · Persbericht

23 september 2026 · New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma · Persbericht

15 september 2026 · RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 · Persbericht

14 september 2026 · Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer · Persbericht

Profiel Johnson & Johnson

Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: www.jnj.com

Hoofdzetel: New Brunswick, New Jersey vlag Verenigde Staten

Mijn selecties